EP Patent

EP3615541A1 — Polymorphs and solid forms of (s)-2-((2-((s)-4-(difluoromethyl)-2-oxooxazolidin-3-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepin-9-yl)amino)propanamide, and methods of production

Assigned to F Hoffmann La Roche AG · Expires 2020-03-04 · 6y expired

What this patent protects

The present invention relates to crystalline polymorph forms of (5)-2-((2-((5)-4-(difluoromethyl)-2-oxooxazolidin-3-yl)-5,6-dihydrobenzo[ƒ]imidazo[ 1,2-J] [ 1,4]oxazepin-9-yl)amino)propanamide (GDC-0077), having the structure, Formula I or stereoisomers, geometric isomers, tautom…

USPTO Abstract

The present invention relates to crystalline polymorph forms of (5)-2-((2-((5)-4-(difluoromethyl)-2-oxooxazolidin-3-yl)-5,6-dihydrobenzo[ƒ]imidazo[ 1,2-J] [ 1,4]oxazepin-9-yl)amino)propanamide (GDC-0077), having the structure, Formula I or stereoisomers, geometric isomers, tautomers, and pharmaceutically acceptable salts thereof, and processes of preparing the polymorph forms.

Drugs covered by this patent

Patent Metadata

Patent number
EP3615541A1
Jurisdiction
EP
Classification
—
Expires
2020-03-04
Drug substance claim
No
Drug product claim
No
Assignee
F Hoffmann La Roche AG
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.